北大医药(000788) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥498,709,845.17, representing a 3.46% increase compared to ¥482,036,482.63 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was ¥16,705,869.02, a significant increase of 40.71% from ¥11,872,378.05 in Q1 2022[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,960,415.93, reflecting a 40.74% increase year-on-year[5] - Basic and diluted earnings per share for Q1 2023 were both ¥0.0280, up 40.70% from ¥0.0199 in Q1 2022[5] - Operating profit for Q1 2023 reached CNY 21,621,826.38, compared to CNY 14,565,050.34 in the previous year, indicating a growth of 48.3%[22] - The net profit for the first quarter of 2023 was CNY 16,693,448.90, representing an increase of 40.5% compared to CNY 11,871,474.86 in the same period last year[24] - The company reported a total profit of CNY 20,942,175.12, which is an increase from CNY 14,050,032.57 year-over-year[24] Cash Flow and Assets - The net cash flow from operating activities was -¥130,571,632.68, a drastic decline of 3,266.62% compared to -¥3,878,417.69 in the previous year[5] - The company's cash and cash equivalents decreased by 41.20% to ¥372,524,823.30, primarily due to reduced cash collections and loan repayments[9] - Cash and cash equivalents decreased to CNY 372,524,823.30 from CNY 633,520,126.20 at the beginning of the year, a decline of 41.1%[20] - Total assets at the end of Q1 2023 were ¥2,457,157,151.47, down 6.83% from ¥2,636,633,493.03 at the end of the previous year[5] - Total assets decreased to CNY 2,457,157,151.47 from CNY 2,637,335,665.00, a reduction of 6.8%[21] - The total cash flow from operating activities was negative CNY 130,571,632.68, a significant decline from negative CNY 3,878,417.69 in the prior year[25] - The cash flow from investing activities was negative CNY 10,790,722.65, compared to negative CNY 2,058,938.77 in the previous year, indicating increased investment outflows[26] - The cash flow from financing activities was negative CNY 142,010,858.86, a significant increase from negative CNY 9,133,912.37 in the prior year[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,837[11] - Southwest Synthetic Pharmaceutical Group Co., Ltd. holds 25.82% of the shares, totaling 153,859,360 shares, with 69,607,360 shares frozen[11] - Peking University Health Management Co., Ltd. holds 11.80% of the shares, totaling 70,328,949 shares[11] - The top ten shareholders include several domestic non-state-owned entities, indicating a diverse ownership structure[11] - As of the end of the reporting period, a total of 69,607,360 shares held by Southwest Synthetic Pharmaceutical Group have been judicially frozen, but this will not affect the company's control or daily operations[14] - The company has not reported any significant impact on corporate governance due to the frozen shares[14] Research and Development - Research and development expenses increased by 70.18% to ¥3,805,765.92, indicating a significant rise in investment in R&D activities[9] Regulatory Approvals and Partnerships - The company received approval from the National Medical Products Administration for the drug supplement application for injectable cefotaxime sodium, which passed the consistency evaluation of generic drug quality and efficacy[13] - The company obtained a drug registration certificate for citric acid tamsulosin tablets, confirming compliance with registration requirements[16] - The company is involved in a partnership to establish a private equity investment fund with a target capital contribution of no less than 500 million RMB and no more than 700 million RMB[15] - The company has completed the deregistration of a fund management company due to historical complexities and lack of actual investment activities[15] Liabilities and Retained Earnings - Total liabilities decreased to CNY 1,063,406,151.62 from CNY 1,260,278,114.05, reflecting a decline of 15.6%[21] - The company's retained earnings increased to CNY 547,916,110.01 from CNY 531,210,240.99, a growth of 3.2%[21]